 Creating quality outcomes
through our financial strength
Highlights 2017
2017 2016
6
Reported 
growth
Growth at 
constant 
currency
1
Group revenue (£ million) 96.9 83.2 16% 12%
Adjusted
2
 operating margin (%) 26.2 23.7 250bps –
Adjusted
2
 profit before tax (£ million) 25.4 19.7 29% –
Profit before tax (£ million) 25.3 19.1 32% –
Adjusted
2
 diluted earnings per share (p) 9.46 7.66 23% –
Diluted earnings per share (p) 9.39 7.38 27% –
Net operating cash flow
3
 pre-
exceptional items (£ million) 21.5 22.3 (4%) –
Net cash (£ million)
4
62.5 51.1 22% –
Proposed final dividend of 0.75p per share, making a total dividend for the year of 
1.10p (2016: 0.92p), up 20%.
Financial
 e Good revenue growth, up 16% to £96.9 million and by 12% 
at constant currency 
•  Branded revenues up 22% to £55.2 million (2016: £45.4 million), 
and by 16% at constant currency
•  OEM revenues up 10% to £41.7 million (2016: £37.8 million) 
and by 8% at constant currency
 e Continued strong performance from LiquiBand
®
 topical tissue 
adhesives, sales up 35% to £26.0 million (2016: £19.3 million) and 
by 30% at constant currency 
•  US revenues up 47% to £18.2 million (2016: £12.4 million) and 
by 40% at constant currency
•  As at 31 December 2017, US market share by volume
5
 increased 
to 26% (June 2017: 24%)
 e RESORBA
®
 branded products up 15% to £20.8 million 
(2016: £18.1 million) and by 6% at constant currency
 e Antimicrobial dressings up 11% to £19.4 million (2016: £17.5 million) 
and by 9% at constant currency
 e Out-licensing deal with Organogenesis signed for a collagen based 
wound dressing containing Polyhexamethylene Biguanide (“PHMB”)
• Royalties of £2.5 million received in 2017 (2016: £nil)
Business
Group revenue
£96.9m
(2016: £83.2m)
6
Adjusted
2
 profit before tax
£25.4m
(2016: £19.7m)
Adjusted
2
 diluted  
earnings per share
9.46p
(2016: 7.66p)
Net cash
4
£62.5m
(2016: £51.1m)
1
 Constant currency removes the effect 
of currency movements by re-translating 
the current period’s performance at the 
previous period’s exchange rates.
2
 All items are shown before exceptional 
items which were £nil (2016: £0.4 million) 
and amortisation of acquired intangible 
assets which, in 2017, were £0.1 million 
(2016: £0.2 million) as defined in the 
Financial Review.
3
 Operating cash flow is arrived at by 
taking the operating profit for the period 
before exceptional items of £nil million 
(2016: £0.4 million), depreciation, 
amortisation, working capital movements 
and other non cash items.
4
 Net cash is defined as cash and cash 
equivalents plus short term investments 
less financial liabilities and bank loans.
5
 Data supplied by Global 
Healthcare Exchange.
6
 2016 Revenue restated as a result of 
adoption of IFRS 15 (Revenue from 
Contracts with Customers).
Company Overview
Strategic Report
Governance
Financial Statements
01 Advanced Medical Solutions Group plc Annual Report 2017
